Skip to content

Effect of neoadjuvant chemotherapy on the antagonistic effect of sugammadex in patients with ovarian cancer after surgery

Effect of neoadjuvant chemotherapy on the antagonistic effect of sugammadex in patients with ovarian cancer after surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091985
Enrollment
Unknown
Registered
2024-11-07
Start date
2024-11-10
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

Chemotherapy group :Neoadjuvant chemotherapy was performed before surgery
Non-chemotherapy group:No neoadjuvant chemotherapy was given before surgery

Sponsors

Jiangsu Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. For patients with FIGO stage ? ~ ? ovarian cancer who were to undergo pelvic lesion resection, preoperative neoadjuvant chemotherapy was determined according to SUDAN score. Patients who received neoadjuvant chemotherapy before surgery were included in cohort 1, and those who did not received neoadjuvant chemotherapy were included in cohort 2. 2.ASA grade I ~ III 3. Age range from 18 ~ 64 4. Body mass index of 18.5 ~ 28kg/m^2 5. Patients or family members sign informed consent

Exclusion criteria

Exclusion criteria: 1. Neuromuscular disease was present before surgery 2. Diabetic patients 3. Long-term use of psychotropic drugs, chronic analgesics and drugs affecting neuromuscular conduction before surgery 4. Allergic reaction to other anesthetic drugs such as neuromuscular blocking drugs before surgery 5. Severe liver and kidney dysfunction or severe heart disease before surgery (NYHA grade ? or ?) 6. History of chemoradiotherapy for other tumors 7. Participated in other clinical studies in 3 months

Design outcomes

Primary

MeasureTime frame
The time from sugammadex administration to Train of Four ratio>=0.9;

Secondary

MeasureTime frame
The onset time of muscle relaxants;Clinical duration time of muscle relaxants;Recovery index of muscle relaxants;Extubation time;Duration of postanesthesia care unit stay;Richmond Agitation-Sedation Scale score;Incidence of respiratory depression;Incidence of re-intubation;Incidence of agitation;Incidence of nausea and vomiting;Numerical rating scale scores;Time to first ambulation;Time to first flatus;Time to first meal;Length of postoperative hospital stay;Total length of hospital stay;The occurrence of postoperative complications;Systolic blood pressure;Diastolic blood pressure;Heart rate;Pulse oxygen saturation;

Countries

China

Contacts

Public ContactXiaolan Gu

Jiangsu Cancer Hospital

xiaolan0652@sina.com+86 131 8281 8002

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026